Elan chief explains J&J's Tysabri option

Tysabri rumors have smoked out Elan CEO Kelly Martin (photo). The flurry of talk about Johnson & Johnson's "arrangement" with Elan on the MS drug prompted Martin to come out with details. And here they are: J&J has an option to help finance Elan's purchase of Biogen Idec's rights to Tysabri in the event that Biogen is acquired. Under that scenario, J&J would end up as Elan's 50-50 partner on the drug.

Martin's remarks come after word started leaking out, with sources speculating in the media that J&J might have outright acquired Elan's right to buy Biogen's Tysabri share. As you know, Elan and Biogen's Tysabri partnership includes a provision granting each company the right to buy Tysabri if the other is acquired. J&J is now Elan's largest shareholder, having bought an 18 percent-plus share of the firm for $1 billion.

Elan granted J&J the option to finance a Tysabri buy because the Irish company couldn't afford to do so by itself, Martin told Bloomberg. "We wanted to make sure we were not flat-footed from a financing point of view," Martin told the news service. "Why on Earth would we ever want to sell our half of the asset?"

- read the Bloomberg story
- get more from the WSJ Health Blog

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.